The risk of poor outcomes in pharmacoeconomic analysis and the evaluation of the safety of remaxol in therapy for chronic viral hepatic lesions (according to the materials of multicenter randomized clinical studies)

Tamara Vasil'evna Sologub; Сологуб Тамара Васильевна; D S Sukhanov; Суханов Д С; A Yu Petrov; Петров А Ю; A L Kovalenko; Коваленко А Л; L G Goryacheva; Горячева Л Г; M G Romantsov; Романцов М Г; T V Sologub; Sologub T V; D S Sukhanov; Sukhanov D S; A Yu Petrov; Petrov A Yu; A L Kovalenko; Kovalenko A L; L G Goryacheva; Goryacheva L G; M G Romantsev; Romantsev M G

doi:10.17816/EID40486

The risk of poor outcomes in pharmacoeconomic analysis and the evaluation of the safety of remaxol in therapy for chronic viral hepatic lesions (according to the materials of multicenter randomized clinical studies)

Authors: Sologub T.V.¹, Sukhanov DS¹, Petrov AY.¹, Kovalenko AL¹, Goryacheva LG¹, Romantsov MG¹, Sologub TV², Sukhanov DS², Petrov AY.³, Kovalenko AL³, Goryacheva LG⁴, Romantsev MG²
Affiliations:
2. I. I. Mechnikov Saint Petersburg State Medical Academy
3. "POLISAN" Scientific-and-Technological Pharmaceutical Firm
4. Research Institute of Childhood Infections, Federal Biomedical Agency
Issue: Vol 15, No 1 (2010)
Pages: 61-64
Section: Articles
URL: https://rjeid.com/1560-9529/article/view/40486
DOI: https://doi.org/10.17816/EID40486
ID: 40486

Cite item

Abstract

The paper presents the results of a study evaluating the efficacy of the succinate-containing solution remaxol in therapy for chronic hepatitis with cytolysis syndrome. The use of remaxol during basic therapy versus placebo has established to result in a more frequent reduction in the activity of a hepatic process and in normalization of biochemical parameters. With this, the relative risks for poor therapy outcomes significantly reduce. Comparative pharmacoeconomic analysis has revealed that the higher cost of the therapy (as compared with placebo) is warranted due to its efficiency. The side effects of therapy have been monitored and the safety of using remaxol in chronic hepatitis is shown: the incidence of side effects requiring drug discontinuation is 0.3%.

Keywords

remaxol, hepatitis, relative risk, pharmacoeconomics, side effects

References

Зарубина И. В., Шабанов П. Д. Молекулярная фармакология антигипоксантов. - СПб., 2004. - С. 17-85.
Ивашкин В. Т. Болезни печени и желчевыводящих путей: Руководство для врачей. - 2-е изд. - М., 2005.
Коваленко А. Л. Фармакологическая активность оригинальных лекарственных препаратов на основе 1-дезокси-1(N-метиламино)-D-глюцитола: Автореф. дис. ... д-ра биол. наук. - СПб., 2005.
Кожока Т. Г. Лекарственные средства в фармакотерапии патологии клетки. - М., 2007.
Куликов А. Ю., Крысанов И. С. // Фармакоэкономика. - 2009. - Т. 2, № 2. - С. 36-43.
Лукьянова Л. Д. // Фармакотерапия гипоксии и ее последствий при критических состояниях. - СПб., 2004. - С. 36-37.
Онищенко Г. Г. // Журн. микробиол. - 2003. - № 4. - С. 93-99.
Радченко В. Г., Шабров А. В., Зиновьева Е. Н. Основы клинической гепатологии. - СПб., 2005. - С. 306-318.
Серпик В. Г. // Фармакоэкономика. - 2009. - Т. 2, № 2. - С. 9-14.
Суханов Д. С., Иванов А. К., Романцов М. Г., Сологуб Т. В. // Вестн. СПбГМА им. И. И. Мечникова. - 2008. - № 4. - С. 186-192.
Суханов Д. С. Лекарственные поражения печени у больных туберкулезом органов дыхания и гепатопротективная терапия: Автореф. дис. ... канд. мед. наук. - СПб., 2008.
Хронические вирусные гепатиты и цирроз печени / Рахманова А. Г., Яковлев А. А., Виноградова Е. Н. и др. - СПб., 2006.
Chap T. L. Introductory Biostatistics. - New Jersey, 2003.
Introduction to Biostatistics: Textbook. - Vienna, 2009.

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

The risk of poor outcomes in pharmacoeconomic analysis and the evaluation of the safety of remaxol in therapy for chronic viral hepatic lesions (according to the materials of multicenter randomized clinical studies)

Full Text

Abstract

Keywords

About the authors

References

Supplementary files

This website uses cookies